Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071201 · ClinicalTrials.gov registry record · Phase 3
Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT00071201 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 48 participants.
The verdict
NCT00071201, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a multi-center phase 3, open-label, parallel-group study designed to evaluate the efficacy, safety and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and varying degrees of renal impairment.
Interventions
- DRUG Adefovir Dipivoxil for oral suspension, 2 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071201
The ClinicalTrials.gov registry entry for NCT00071201 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adefovir Dipivoxil for oral suspension, 2 mg/mL is the first listed.
NCT00071201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071201 about?
NCT00071201 is a clinical study titled "Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B". This is a multi-center phase 3, open-label, parallel-group study designed to evaluate the efficacy, safety and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and varying degrees of renal impairment.
What is the current status of trial NCT00071201?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2003-06. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00071201?
The interventions under investigation include: Adefovir Dipivoxil for oral suspension, 2 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00071201?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.